LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Authors

Yi Long Wu

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Yi Long Wu , Caicun Zhou , Cheng-Ping Hu , Ji Feng Feng , Shun Lu , Yunchao Huang , Wei Li , Mei Hou , Jian Hua Shi , Kye Young Lee , Dan Massey , Yang Shi , Jiongjie Chen , Victoria Zazulina , Sarayut Lucien Geater

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.

First Author: Sarayut Lucien Geater

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs.

First Author: Giuseppe Altavilla

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

First Author: C. Zhou

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC).

First Author: B. H. Grønberg